Submission Details
| 510(k) Number | K233253 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 28, 2023 |
| Decision Date | June 21, 2024 |
| Days to Decision | 267 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
K233253 is an FDA 510(k) clearance for the eCARTv5 Clinical Deterioration Suite (?eCART?), a Medium-term Adjunctive Predictive Cardiovascular Indicator (Class II — Special Controls, product code QNL), submitted by Agilemd, Inc. (San Francisco, US). The FDA issued a Cleared decision on June 21, 2024, 267 days after receiving the submission on September 28, 2023. This device falls under the Cardiovascular review panel. Regulated under 21 CFR 870.2210.
| 510(k) Number | K233253 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 28, 2023 |
| Decision Date | June 21, 2024 |
| Days to Decision | 267 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
| Product Code | QNL — Medium-term Adjunctive Predictive Cardiovascular Indicator |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 870.2210 |
| Definition | The Adjunctive Predictive Cardiovascular Indicator Is A Prescription Device That Uses Software Algorithms To Analyze Cardiovascular Vital Signs And Predict Future Cardiovascular Status Or Events Within A Defined Medium-term Period. This Device Is Intended For Adjunctive Use With Other Physical Vital Sign Parameters And Patient Information And Is Not Intended To Independently Direct Therapy. |